Analyst Reco. bluebird bio, Inc.

Equities

BLUE

US09609G1004

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-02 EDT			5-day change	1st Jan Change
0.9033 ^USD	-0.66%		-2.12%	-34.54%

04-26	Bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report	MT
03-27	Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating	03-27	MT
Wedbush Adjusts bluebird bio's PT to $1.72 From $1.68, Maintains Neutral Rating	03-27	MT
Wedbush Adjusts Bluebird Bio Price Target to $1.72 From $1.68, Maintains Neutral Rating	03-26	MT
Wedbush Adjusts bluebird bio's Price Target to $1.68 From $3, Maintains Neutral Rating	03-19	MT
HSBC Adjusts bluebird bio's Price Target to $1.02 From $2.31, Keeps Reduce Rating	03-05	MT
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment	12-19	DJ
Wells Fargo Adjusts Bluebird Bio Price Target to $5 From $8, Maintains Equal Weight Rating	12-15	MT
Baird Adjusts Price Target on bluebird bio to $7 From $10, Maintains Outperform Rating	12-12	MT
BofA Securities Adjusts Price Target on bluebird bio to $12 From $11, Maintains Buy Rating	12-11	MT
Wedbush Lowers bluebird bio's PT to $3 From $5, Says Black Box Warning for Lyfgenia Makes it Difficult to Justify Premium; Maintains Neutral Rating	12-11	MT
Top Stories at Midday: Unemployment Rate Falls; Carrier Global Rises on Honeywell Deal; Tesla's Norway Labor Woes; FDA Approves Casgevy, Lyfgenia; Putin's 2024 Presidential Run	12-08	MT
Morgan Stanley Upgrades Bluebird Bio to Equalweight From Underweight, Boosts Price Target to $7 From $3	12-08	MT
Wedbush Lowers bluebird bio's Price Target to $5 From $7, Maintains Neutral Rating	11-08	MT
Cantor Fitzgerald Initiates Coverage on bluebird bio with Neutral Rating	23-10-17	MT
HSBC Initiates bluebird bio With Buy Rating, Price Target is $4.21	23-09-06	MT
BofA Securities Upgrades bluebird bio to Buy From Neutral on Gene Therapy Potential, Adjusts Price Target to $10 From $6	23-07-19	MT
BofA Securities Upgrades bluebird bio to Buy From Neutral, Adjusts Price Target to $10 From $6	23-07-19	MT
RBC Trims bluebird bio's Price Target to $6 From $8, Keeps Sector Perform Speculative Risk Rating	23-07-07	MT
Barclays Upgrades bluebird bio to Overweight From Equalweight, Adjusts Price Target to $8 From $7	23-06-01	MT
Wedbush Adjusts bluebird bio Price Target to $7 From $5, Maintains Neutral Rating	23-05-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. bluebird bio, Inc.

Equities

BLUE

US09609G1004

Analyst Reco.

Filters